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Abstract
Background: Virtual screening is used to distinguish potential leads from inactive compounds in
a database of chemical samples. One method for accomplishing this is by docking compounds into
the structure of a receptor binding site in order to rank-order compounds by the quality of the
interactions they form with the receptor. It is generally established that docking can be reasonably
successful at generating good poses of a ligand in an active site. However, the scoring functions that
are used with docking are typically not successful at correctly ranking ligands according to binding
affinity or even distinguishing correct poses of a given ligand from incorrect ones.
Results: We have developed a simple method for reducing the number of false positives in a virtual
screen, meaning ligands which are scored highly by the docking program but do not bind well in
reality. This method uses a docking program for pose generation without regard to scoring,
followed by filtering with receptor-based pharmacophore searches. We applied it to three test-
case targets: neuraminidase A, cyclin-dependent kinase 2, and the C1 domain of protein kinase C.
Conclusion: The pharmacophore filtering method can perform better than more traditional
docking + scoring methods, and allows the advantages of both docking-based and pharmacophore-
based approaches to virtual screening to be fully realized.
Background
The goal of virtual screening is to select, relatively rapidly
and cheaply, a small subset of compounds predicted to
have activity against a given biological target out of a large
database of compounds. While it is possible to screen
large databases in their entirety using automated high-
throughput screening methods, this is expensive and
requires a substantial investment in infrastructure and
assay development. The idea of virtual screening is to test
compounds computationally in order to reduce the
number of compounds to be screened experimentally,
with the additional advantage that the number of com-
pounds in the final set can easily be adjusted according to
the resources available for assaying.
The database used for virtual screening can be a collection
of commercially available compounds, such as ZINC [1]
or the ChemNavigator iResearch Library [2], both of
which are meta-collections of supplier catalogs. Pharma-
ceutical companies typically have an in-house database of
previously synthesized molecules. A publicly available
alternative to this is the open NCI database [3], a collec-
tion of compounds that have been tested over the past few
decades in the National Cancer Institute's screens for anti-
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cancer activity. Small samples from a subset of this collec-
tion are available for research purposes upon request [4].
A variety of computational methods can be used for vir-
tual screening depending on the desired size of the final
subset and on the amount of information known about
the target, its natural ligands, and any known inhibitors.
Here we focus on the method of receptor-ligand docking
and scoring, which can be used when a three-dimensional
structure of the target is available. This method can be
divided into two parts: first docking  to position ligand
structures into the target binding site, generating a set of
poses for each ligand; and secondly scoring to evaluate and
rank-order poses and ligands according to how well each
pose for each ligand fits into the binding site and the qual-
ity of the interactions it forms with the target. Generally,
in these methods the ligand has conformational flexibility
while the receptor remains essentially rigid. The output
from the docking program is thus a set of poses saved for
each ligand, with a numerical score for each pose.
The main problem with virtual screening is that many,
and in some cases the vast majority, of the compounds
that are predicted to be active are in fact not active when
screened experimentally. There are two theories found in
the literature on the reasons for this phenomenon. Some
researchers argue that docking can usually generate good
poses of a ligand in an active site, however scoring func-
tions are generally not successful at correctly ranking
either ligands or poses [5]. Others have pointed out that
docking programs do not always generate correct poses,
and that the highest ranked pose for a given ligand is often
incorrect. Scoring functions would therefore function
much better at ranking if docking programs did not pro-
duce so many incorrect poses for each compound [6,7].
Regardless of whether it is the docking programs or the
scoring functions that are at fault, the issue is that virtual
screening can generate an enormous number of false pos-
itives – compounds that are scored highly in silico but do
not actually bind to the target in vivo or in vitro. These false
positives can also be blamed to some extent for false neg-
atives, in the case where true positives are scored relatively
poorly (and perhaps even eliminated) because of spuri-
ously high-scoring false positives that are ranked ahead of
them. A method of eliminating at least some of these false
positives at some stage in the virtual screening procedure
would therefore be very useful.
Here we present such a method, which we call pharma-
cophore filtering. It is a means of post-processing docking
results to rapidly eliminate poses and molecules that are
not fully chemically compatible with the binding site.
This includes, for example, poses that do not completely
fill the site, or that leave unpaired buried hydrogen bond
donors or acceptors. This method could be viewed as an
enforcement of the basic principle of structure-based drug
design, namely that good-binding ligands must be chem-
ically complementary to their receptors.
The advantages of including information about the target,
such as specific, required hydrogen bonds into docking
simulations is already well-appreciated [8]. One advan-
tage of our method over others is that it allows multiple
such target-ligand interactions to be quickly tested, com-
pared and re-adjusted without re-running the entire dock-
ing calculation. Thus it is a useful addition to the virtual
screening arsenal, and as we attempt to demonstrate here,
it is broadly applicable to a variety of targets and ligand
design goals.
Results
Pharmacophore Filtering Method Description
The pharmacophore filtering method begins by using a
docking program in the ordinary way, for pose generation
and alignment in the binding site. All the poses output by
the docking program are saved to a file, while their scores
and rankings are ignored. Next, the docked poses are
searched and filtered using a series of pharmacophore
query models. The pharmacophores are elucidated based
on available crystal structures of bound ligands and/or
simple examination of the binding site, and are used to fil-
ter the saved poses output from the docking program, and
remove any that are incompatible with the model. This
method thus adds an element of ligand-based drug design
to what is essentially a structure-based drug design
method of docking and scoring.
Figure 1 gives a cartoon illustration of this methodology.
In the center is shown a simple four-residue binding site.
A ligand that binds well to this site must have a hydrogen
bond donor group in the region marked with a blue circle
in order to interact with the glutamate residue and the
backbone carbonyl, and a hydrogen bond acceptor group
in the region marked with a red circle to interact with the
arginine residue. The set of saved poses from the docking
program, shown around the edges of the figure, is then
compared with this model for good binding. Unlike a tra-
ditional pharmacophore search, the ligands do not need
to have low-energy conformers generated, or be translated
or rotated to align to the pharmacophore hypothesis
because they have already been aligned to one another in
the coordinate space of the binding site by the docking
program. Thus it is computationally inexpensive to step
through the poses and check them against the pharma-
cophore model, and quickly eliminate those that do not
fulfill the necessary interactions.
Clearly this method works best when at least one co-crys-
tal structure with the natural ligand or an inhibitor isJournal of Cheminformatics 2009, 1:6 http://www.jcheminf.com/content/1/1/6
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available, but it would also in theory be possible to use an
apo structure and examine the interactions made with
water. There are no special restrictions on what software to
use, though it is probably better if the docking program
has a stochastic component and can generate diverse
poses rather than converging on a "best solution." In the
test cases for this method, described below, we used the
well-known docking programs GOLD [9] and Glide [10].
Rather than using a full-blown pharmacophore genera-
tion and search program, it is possible to simply filter the
output file of docked poses according to whether or not
they fulfill certain receptor-ligand contacts or interactions.
For example, with Glide, Schrödinger provides a "Pose-
Filter" Python script to perform this type of filtering, and
for GOLD, such an analysis can be done with its compan-
ion programs Hermes and GoldMine. However, a dedi-
cated pharmacophore program will provide more options
and greater flexibility in defining the filters to be used.
The pharmacophore program must allow the import of a
set of pre-generated conformers that are pre-aligned to the
pharmacophore model. The site points in the pharma-
cophore model can be defined based on either the posi-
tions of ligand atoms (ligand-sided) or the positions of
receptor atoms (protein-sided), or both, depending on
the nature of the interaction to be captured with the filter.
The radius of the site points can also be adjusted to alter
the sensitivity of the model. A smaller radius gives a
tighter, more selective filter, whereas a larger radius can
capture some flexibility of ligands within the binding site
or account for some variability in binding modes. For our
test cases the pharmacophore models were generated in
MOE [11] by simple visual inspection of crystal structure
binding sites and co-crystallized ligands, along with infor-
mation on the binding modes of other known ligands
from the literature.
Alternately, there are several published methods and soft-
ware programs available for automatically or semi-auto-
matically generating structure-based pharmacophore
models. For example, the program LUDI [12] (currently
commercially available as part of Discovery Studio from
Accelrys) calculates an interaction map of locations in the
receptor binding site where an atom from a bound ligand
would be in position to form a favorable hydrogen-bond-
ing or hydrophobic interaction. This map can then be
converted into a pharmacophore model. Another such
A cartoon illustration of the pharmacophore filtering method Figure 1
A cartoon illustration of the pharmacophore filtering method. A hypothetical binding site is shown in the central box, 
with interaction site points for a hydrogen bond donor (blue circle), and a hydrogen bond acceptor (red circle). A hypothetical 
set of docked poses is shown around the edges, superimposed on the interaction sites. The only pose which passes the filters 
and fits the binding site is circled while the others are crossed out.Journal of Cheminformatics 2009, 1:6 http://www.jcheminf.com/content/1/1/6
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program is LigandScout [13], which is a fully automated
method of generating a pharmacophore model from a set
of protein-ligand complexes.
Test Cases
We evaluated our methodology with three test cases: pro-
tein targets of pharmaceutical relevance with a variety of
binding site characteristics.
Neuraminidase A
Influenza neuraminidase A is a surface glycoprotein of the
influenza virus whose function is to cleave the linkage
between sialic acid and an adjacent sugar in glycoconju-
gates on the surface of cells targeted for infection [14]. The
sialic acid binding site is small, deep, and highly polar.
For this target, there existed a literature reference examin-
ing which of the many available crystal structures of neu-
raminidase is best suited for docking a variety of ligands
[15]. Based on this study's conclusions, we chose the
1MWE crystal structure [16], which has good (1.7 Å) res-
olution and could accommodate all members of a set of
co-crystallized ligands [15]. To prepare the structure for
docking, we deleted all bound ligands and crystallo-
graphic waters and flipped the orientation of residue Asn
294 in the binding site (the sidechain amide nitrogen and
oxygen had been assigned incorrectly).
The screening database for this test case was constructed
by first downloading a set of 245 neuraminidase ligands
from the BindingDB [17,18]. Ligands with Ki or IC50 val-
ues of 10 μM or lower (195 compounds) were considered
actives. The inactive ligands were added to a set of 4775
decoys obtained from both the MDL Drug Data Report
database (MDDR) [19] and the ChemNavigator iResearch
Library (iRL) [2] of commercially available compounds.
The decoys were filtered using Pipeline Pilot [20] to
choose compounds whose physicochemical properties fit
into the ranges seen with the known neuraminidase lig-
ands. This was to ensure that the docking and scoring pro-
tocols were not biased in distinguishing hits from decoys
due to differences in their property distributions. In this
case, decoys were required to have a molecular weight
between 190 and 500, a logP between -7.5 and 4.0, a polar
surface area between 95 and 250 Å2, fewer than 10 rotata-
ble bonds, at least 3 hydrogen bond donors and at least 2
hydrogen bond acceptors. Thus the final set of 4775
decoys were all as small and highly polar as the set of
known neuraminidase binders.
The screening database was docked into the binding site
using two docking programs, GOLD 3.0.1 [9] and Glide
4.0 [10]. In GOLD, the binding site was defined as a
sphere with a radius of 10 Å centered at the position of
atom C6 in the bound sialic acid ligand. We used the 7–
8x speedup rather than the library screening settings for
the genetic algorithm, for some sacrifice in speed but an
improvement in the quality of the generated poses, and
the Goldscore scoring function. In Glide, the protein
structure was prepared using the Protein Preparation and
Grid Generation modules, with all default settings. For
docking we used the HTVS precision mode, with all other
parameters left in their default settings. With both pro-
grams, ten poses were saved for each compound, then all
the saved poses from both programs were submitted to
pharmacophore filtering (see below). For comparison
purposes, all the saved poses from both programs were
also re-scored with a total of four different scoring func-
tions: GScore in Glide, Goldscore and Chemscore as
implemented in GOLD, and an "Affinity" score. This latter
score is a reformulation of two of the terms in the Gold-
score scoring function, defined as hbond.external  +
1.375*vdw.external, and has been shown to correlate bet-
ter with experimental binding affinities than Goldscore
itself, which was optimized to give good poses [21].
The pharmacophore filters used for neuraminidase are
shown relative to the binding site in Figure 2[22]. To
develop these filters we first reproduced the docking of a
set of 21 co-crystallized ligands back into the 1MWE crys-
tal structure, as was done by Birch et al. in their analysis
[15]. This set of superimposed docked ligands along with
the binding site residues were then imported into the
pharmacophore query editor in MOE [11]. All of the lig-
ands contain a carboxylic acid or phosphate group that
interacts with three strictly conserved arginine residues
(Arg 118, 292, and 371) [14] in the so-called acid binding
sub-pocket of the binding site. Since the charged oxygens
in these acidic groups were tightly superimposed, we built
two ligand-sided site points (meaning that they were cen-
tered over the positions of the superimposed ligand
atoms) on these oxygens, as shown in Figure 2A. This cre-
ated the first filter, to select for docked poses in the screen-
ing database with hydrogen bond acceptor atoms or
negatively charged atoms in position to interact with the
arginine residues.
Another sub-pocket of the binding site holds an acetyl
group via a hydrogen bond from the carbonyl oxygen to
Arg 152, and a hydrophobic interaction of the methyl
group with residues Ile 222 and Trp 178 [14]. We con-
structed a second filter for this interaction with a ligand-
sided hydrogen bond acceptor or anionic site point and a
ligand-sided hydrophobic site point (Figure 2B).
Finally, the third filter took into consideration the three
highly conserved glutamate residues with unpaired accep-
tor atoms across the center of the binding site (Glu 119,
227, and 276) [14]. The superimposed co-crystal ligands
showed a variety of methods of interacting with these
glutamates, so we built receptor-sided site points (mean-Journal of Cheminformatics 2009, 1:6 http://www.jcheminf.com/content/1/1/6
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The sialic acid binding site and the three pharmacophore filters defined for neuraminidase A Figure 2
The sialic acid binding site and the three pharmacophore filters defined for neuraminidase A. A) Site points, 
shown as red-dotted spheres, indicate the required positions of hydrogen bond-accepting or negatively charged atoms to inter-
act with arginine residues in the acid binding sub-pocket. B) The required position of an atom forming a hydrogen bond to Arg 
152 (red-dotted sphere) along with a hydrophobic interaction (yellow-dotted sphere). C) Blue-dotted spheres indicate the 
space available for atoms forming hydrogen bonds or salt bridges to three glutamate residues. This figure was generated using 
PyMOL [22].
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Bar chart illustrating filtering rates for actives vs. decoys with neuraminidase A Figure 3
Bar chart illustrating filtering rates for actives vs. decoys with neuraminidase A. The percentages of actives (true 
positives) and decoys (false positives) that remain in the docked database after each of the pharmacophore filters. The absolute 
number in each group of compounds is marked at the top of the bars.
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ing that they were centered on oxygen atoms in the gluta-
mate residues of the receptor) for hydrogen bond donor
or positively charged atoms, with a radius of about 3 Å to
allow for the hydrogen bonding distance to ligand atoms
(Figure 2C). The filter required an interaction with at least
one of the glutamates.
The bar chart in Figure 3 illustrates schematically the abil-
ity of each of the three pharmacophore filters, applied
sequentially, to selectively remove false positives (decoys)
out of the set of docked poses while retaining true posi-
tives (known actives). The three filters dramatically reduce
the number of decoys down to approximately 1% of their
original number, while keeping nearly 90% of the true
positive compounds. By the last filtering step, the starting
set of 4970 compounds has been reduced to only 224,
which might be a reasonable number for a small-scale
experimental screen. This final hit set has about three
times as many true actives as decoys.
To compare these results to the traditional scoring func-
tion approach, in Figure 4 the final hit set after filtering
has been ranked numerically by docking score, and is
plotted on a standard enrichment plot (percentage of
actives found vs. percentage of database screened), along
with the original set of all the docked compounds ranked
by each of the four scoring functions. Neuraminidase is
not a target that is particularly challenging for most dock-
ing programs, as illustrated by the fact that both Glide/
Gscore and Gold/Affinity are able to rank over 90% of the
actives in approximately the first 10% of the database.
Nevertheless there is still a clear improvement in enrich-
ment with the pharmacophore filtering. Another point
that can be highlighted here is that while it is often diffi-
cult to know with scoring functions what cutoff to use for
delineating good scores from bad scores, or good com-
pounds from bad compounds, with the pharmacophore
filtering method an automatic cutoff is built in, as shown
by the dashed line in Figure 4 indicating the point beyond
which no structures had any poses that passed all three fil-
ters in the pharmacophore model. This eliminates over
Enrichment plot for neuraminidase A Figure 4
Enrichment plot for neuraminidase A. Comparison of the percentage of known actives retrieved vs. the percentage of 
the test database screened for the pharmacophore filtering method (black line) and traditional docking + scoring methods.
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95% of the starting database from further consideration.
Thus instead of requiring the somewhat arbitrary selection
of the top N molecules from a list ranked by docking
score, the pharmacophore filtering method produces the
clear result that 224 compounds are worthy of further
consideration, either with experimental screening or with
more detailed modeling work.
Cyclin-dependent kinase 2 (CDK2)
The family of cyclin-dependent kinases are regulators of
the cell cycle. In particular CDK2, in complex with cyclins
E and A, is involved in the G1-S transition and the pro-
gression through S phase, although it has recently been
shown not to be essential for mitotic cell division in mice
[23]. Like all other kinases, CDK2 has an ATP binding site
located in a cleft between the N-terminal and C-terminal
lobes of the protein. Here again, as with neuraminidase,
we consulted the literature to determine which of the
available crystal structures would be best suited for virtual
screening. There is a published study examining a diverse
subset of 20 of the available CDK2 crystal structures, and
we chose the one that performed best at docking the most
structurally diverse group of CDK2 inhibitors [24]. This
crystal structure, 1OIT, is in an active, open conformation
and has a high crystallographic resolution of 1.6 Å [25].
Several loop regions in the structure were disordered and
coordinates for these were not present. We capped all such
protein chain ends, including the N- and C-termini, with
hydrogens to form neutral NH2 and COOH groups. We
also built coordinates for the missing sidechain of residue
Lys 9, which is near the binding site, in a conformation
pointing out into solvent with a χ1 angle of -60°.
Along the same lines as with neuraminidase, the screening
database was constructed by first downloading a set of
1278 CDK2 ligands from the BindingDB [17,18]. Ligands
with Ki or IC50 values of 10 μM or lower (1063 com-
pounds) were considered active, and the inactive ligands
were added to a set of 26792 decoys combined from the
MDDR [19] and ChemNavigator iRL [2] databases. These
decoys were filtered using Pipeline Pilot [20] to choose
compounds physicochemically similar to known kinase
inhibitors, with a molecular weight between 200 and 550,
at least two aromatic rings, a logP between 0.5 and 6.0, a
polar surface area of less than 150 Å2, fewer than 10 rotat-
able bonds, less than 4 hydrogen bond donors and
between 2 and 8 hydrogen bond acceptors.
The screening database was docked into the binding site
using both GOLD [9] and Glide [10], with the same set-
tings used as before with neuraminidase. In GOLD, the
binding site was defined as a sphere with a radius of 10 Å
centered at the position of atom C14 in the bound ligand.
Ten docked poses were saved for each compound from
each program, and all the poses were again submitted to
pharmacophore filtering. All the saved poses were also re-
scored as before with the four scoring functions: GScore,
Goldscore, Chemscore, and GOLD Affinity.
The pharmacophore filters used for CDK2 are shown in
Figure 5[22]. To develop these filters, we proceeded in a
similar way as for neuraminidase and docked a small set
of 12 co-crystallized CDK2 ligands back into the 1OIT
binding site [24]. The set of superimposed docked ligands
along with the binding site residues were then imported
into the pharmacophore query editor in MOE [11]. Both
pharmacophore filters for this target used ligand-sided site
points. The first filter (Figure 5A) was constructed to select
for poses with hydrogen bonds to the hinge region of the
binding site, a standard kinase inhibitor feature. There are
three possible hydrogen bonds that can be formed, to Leu
83 NH, Leu 83 O, or Glu 81 O. The filter required at least
two out of three of these to be present. The second filter
(Figure 5B) selected for ligands of the right size and shape
to fill the hydrophobic adenine region of the binding site,
interacting with residues Phe 80, Val 18, Ile 10, Leu 134,
and/or Ala 31.
The bar chart in Figure 6 illustrates how well these two
pharmacophore filters selected for true positives (known
actives) over false positives (decoys) in the set of docked
poses. Here the filtering is not as successful at separating
actives from decoys as with neuraminidase, but the
number of decoys is reduced down to about 10% of the
starting number, while over 75% of the true active com-
pounds are retained.
The enrichment in the pharmacophore-filtered poses (Fig-
ure 7) is again improved over the best-performing scoring
function, which is Glide/GScore. As before, the pharma-
cophore filtering creates a natural cut-off point (shown by
the dashed line in Figure 7) for separating good com-
pounds from bad compounds. Less than 15% of the full
database passes both filters, and all other compounds can
be concluded to be either incompatible with the binding
site, or to have been misdocked, and therefore can be
safely ignored.
To further refine these results, we looked for subsets of
compounds in the set of CDK2 ligands from the
BindingDB that exploit a particular non-conserved region
in the active site to give selectivity for CDK2 over other
kinases and other members of the CDK family. Some
CDK2 ligands that have a sulfonamide group that is posi-
tioned to interact with a lysine residue (Lys 89) on the top
edge of the binding site, adjacent to a phenyl ring (Phe
82) that packs into a small secondary hydrophobic pocket
or slot above the hinge region (Figure 8A). These ligands
include oxindole-based compounds [26], imidazo [1,2-
a]pyridines [25], and imidazo [1,2-b]pyridazines [27].Journal of Cheminformatics 2009, 1:6 http://www.jcheminf.com/content/1/1/6
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There were 129 molecules in the set of CDK2 ligands that
fit this profile. A final pharmacophore filter was set up in
MOE [11] to look specifically for compounds that can
make these interactions that confer CDK2 specificity (Fig-
ure 8A). This filter was built with a protein-sided acceptor
or anionic site point centered on the Nζ atom of Lys 89,
and a hydrophobic or aromatic site point positioned to
interact with residues Ile 10 and Phe 82. With this filter,
we were able to extract nearly 90% of the 129 active com-
pounds in the subset, and the number of decoys was
reduced to less than 3% of their starting number (Figure
8B).
Protein kinase C (PKC) C1 domain
Protein kinase C isozymes are a family of serine/threonine
kinases which are centrally involved in cell signaling. The
regulatory C1 domain is a 50-residue zinc-finger-like
structure that responds to the second messenger diacylg-
lycerol (DAG) by translocating PKC to the cell membrane,
where the whole protein undergoes a conformational
change and the kinase domain becomes activated [28].
This test case was a more difficult target. The natural acti-
vator is a lipid, and other known ligands are all also
lipophilic natural products [29] and derivatives thereof
[30]. Furthermore, the binding site in the C1 domain is a
half-site in that ligands make interactions with the C1
domain itself, but interactions with lipids in the cell mem-
brane are also important for binding [31]. There is only
one holo C1 domain crystal structure (1PTR) available in
the PDB, with phorbol ester (a natural tumor promoter
and DAG mimetic) in the binding site [32].
The screening database consisted of a small collection of
27 known C1 domain ligands [29,30,33], along with a set
of 1096 natural product decoys from several databases:
the Natural Products subset of the Open NCI Database
[34], a database of compounds used in traditional Chi-
nese medicine [35], and a database of natural products
isolated from marine species [36]. As with the other two
test cases, we selected decoys using Pipeline Pilot [20] that
were physicochemically similar to the known ligands.
Decoys were required to have a molecular weight greater
than 250, a logP between 0.5 and 6, at least three hydro-
gen bond acceptors and at least one hydrogen bond
donor, less than 250 Å2 of polar surface area, and more
than 220 Å2 of non-polar surface area. High-quality three-
dimensional structures for these often-complex molecules
were generated using CORINA [37].
The screening database was docked, as before, with GOLD
[9] and Glide [10]. Due to the fact that the natural prod-
ucts tended to be large compounds with many rotatable
bonds, we used standard precision docking in Glide and
the default genetic algorithm settings in GOLD rather
than high-throughput or speeded-up screening settings,
and we increased the sampling by saving 20 poses for each
compound. In GOLD, the binding site was defined as a
sphere with a radius of 10 Å centered at the position of the
The ATP binding site and the two pharmacophore filters defined for CDK2 Figure 5
The ATP binding site and the two pharmacophore filters defined for CDK2. A) The required locations for hydrogen 
bond-donating atoms (blue-dotted spheres) and a hydrogen bond-accepting atom (red-dotted sphere) in the hinge region. B) 
Overlapping yellow-dotted spheres delineating the space to be filled by hydrophobic packing in the main pocket of the binding 
site. This figure was generated using PyMOL [22].
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Nε atom in residue Gln 257. All saved poses were submit-
ted to pharmacophore filtering, and also re-scored as
before with the four scoring functions: GScore, Goldscore,
Chemscore, and GOLD Affinity.
The pharmacophore filters used are shown in Figure 9[22]
and were based on the hydrogen bonding interactions
seen between the co-crystallized phorbol ligand and the
C1 domain binding site [32]. First (Figure 9A), we used a
ligand-sided site point to select for poses with a functional
group at the bottom of the binding site acting as both a
donor and an acceptor, and forming hydrogen bonds to a
backbone carbonyl oxygen on one side of the binding site
(Leu 251) and to a backbone nitrogen on the other side of
the binding site (Thr 242). Secondly (Figure 9B), we
looked for poses that could form a hydrogen bond to a
glycine residue (Gly 253) on the outer edge of the binding
site, via a protein-sided acceptor site point centered on its
backbone N atom. These two interactions are believed to
be conserved across all known C1 domain ligands
[29,38]. The final filter simply selected for poses with a
certain amount of hydrophobic bulk located in the region
above the binding site, that would be in position to inter-
act with the lipid membrane and with hydrophobic resi-
dues around the edge of the site. At least two of the five
site points shown in Figure 9C were required by the filter.
The performance of the pharmacophore filters is shown in
the bar chart in Figure 10. Of the original set of 27 known
ligands all but one passed through all three filters, and
that compound had 22 rotatable bonds and so it was mis-
docked as both docking programs had difficulty with it.
The number of decoys was reduced to about 5% of the
starting number. The enrichment plot, Figure 11, shows
that the pharmacophore filtering method performed sub-
stantially better with this target than any of the traditional
scoring functions. This is probably due to the hydropho-
bic nature of the binding site and the relatively small
number of polar interactions. The cut-off point generated
by the pharmacophore filtering (the dashed line in Figure
11) gives a final hit set of only 78 compounds.
Discussion
In all three of the test cases at least one crystal structure of
the target and a collection of known inhibitors were avail-
able, allowing us to use properties calculated for known
inhibitors to make rational decisions on the ranges of val-
ues for physicochemical properties that are reasonable for
new potential inhibitors of the target. We used the struc-
Bar chart illustrating filtering rates for actives vs. decoys with CDK2 Figure 6
Bar chart illustrating filtering rates for actives vs. decoys with CDK2. The percentages of actives (true positives) and 
decoys (false positives) that remain in the docked database after each of the pharmacophore filters. The absolute number in 
each group of compounds is marked at the top of the bars.
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tural characteristics of the binding site and the observed
interactions between target and ligands to choose the
parameters used in docking and scoring in order to repro-
duce known inhibitor binding modes, and for analysis of
the docked poses with the pharmacophore filtering
method. We have shown here that, compared to simply
ranking the poses output by the docking program accord-
ing to a single docking score, an initial filtering of the
docked poses with a pharmacophore query to remove
poses that do not form certain essential interactions with
the target binding site greatly improves the quality of the
results. Typically we have seen the ability to eliminate well
over 90% of the decoy molecules in the starting database
while retaining about 80% of the true positives.
This pharmacophore filtering method is in many ways
similar to other approaches that attempt to add additional
information to improve the results from docking and
scoring. We will briefly delineate them, and then discuss
what we believe are the advantages of the method pre-
sented here. One alternative way to incorporate the use of
pharmacophores into a virtual screening protocol is to use
them for pre-screening, rather than post-screening, the
docking database. Such a strategy has been used success-
fully with several targets [39,40], and has the advantage of
reducing the size of the database to be docked. A variation
on this method is called pharmacophore-based molecular
docking, or PhDOCK [41], as it is a variation of the DOCK
program. A database of conformers is overlaid according
to 3D pharmacophores and the pharmacophore site
points are then matched with docking site points in the
binding site. This allows the simultaneous docking of
many molecules at once. The docking site points can
either be generated from standard DOCK "spheres" or can
be based on the positions of atoms in crystallographic lig-
ands. The advantage of these pre-screening methods is
that they can significantly shorten the amount of compu-
ter time required for docking, though this becomes less
and less relevant as computer speed increases and compu-
ter clusters become more common.
Enrichment plot for CDK2 Figure 7
Enrichment plot for CDK2. Comparison of the percentage of known actives retrieved vs. the percentage of the test data-
base screened for the pharmacophore filtering method (black line) and traditional docking + scoring methods.
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Secondary pharmacophore filter for CDK2 Figure 8
Secondary pharmacophore filter for CDK2. A) The ATP binding site with specificity-conferring interactions: the position 
of an atom accepting a hydrogen bond from Lys 89 (red-dotted sphere) and a hydrophobic interaction (yellow sphere). This fig-
ure was generated using PyMOL [22]. B) Bar chart showing the percentage of hits (known actives) compared to decoys that 
are left in the test database after this pharmacophore filter is applied. The absolute number in each group of compounds is 
marked at the top of the bars.
0
10
20
30
40
50
60
70
80
90
100
P
e
r
c
e
n
t
 
R
e
m
a
i
n
i
n
g
K89 Filter
Actives
Decoys
763
111
AB
K89
F82
The C1 domain diacylglycerol binding site and the three pharmacophore filters defined for PKC Figure 9
The C1 domain diacylglycerol binding site and the three pharmacophore filters defined for PKC. A) The 
required position of a hybrid donor/acceptor group (purple-dotted sphere). B) The space available for a hydrogen bond-
accepting atom forming a key interaction with Gly 253 (red-dotted sphere). C) Hydrophobic groups (yellow-dotted spheres) in 
position to interact with the lipid bilayer. This figure was generated using PyMOL [22].
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A second method of incorporating pharmacophores into
virtual screening is to post-process docking results with
various kinds of ligand interaction-based filters. One such
method is the structural interaction fingerprint [42], or
molecular interaction fingerprint [43], which encodes
into a binary bit string the set of binding interactions
made by a docked ligand pose. These strings can be clus-
tered and compared using Tanimoto similarities, and
used to rapidly filter poses for the presence or absence of
specific interactions, providing an improvement in virtual
screening hit list enrichment over conventional scoring
functions. Similarly, an interactions-based accuracy classi-
fication method [44] has been shown to provide a supe-
rior assessment of docking pose quality compared to
simple RMS deviations from crystal structure poses.
Rather than applying pharmacophores to filter docked
poses directly, the AutoShim method [45] uses point
pharmacophore interaction features in the binding site to
weight or "shim" the docking scoring function according
to experimental IC50 data for the target receptor, and can
produce large improvements in the ability of the scoring
function to predict binding affinities. In contrast, the
pharmacophore filtering method presented here requires
no additional new or proprietary software unlike these
other methods for post-processing docking results – only
a docking program and a pharmacophore generation pro-
gram, both of which are highly likely to be in use by any
modeling group.
Finally, a third method of incorporating pharmacophores
into virtual screening is to add constraints to the docking
run to ensure that certain interactions between the ligands
and the target binding site are formed. Such pharmacoph-
oric constraints can be implemented in GOLD [46] as well
as in many other modern docking programs, and are the
basis for the screening program FlexX-Pharm [47], where
ligands are incrementally constructed into the active site
in a manner incorporating "look-ahead checks" to ensure
that desired interactions are formed. These types of con-
straints are particularly useful with kinases, in which
hydrogen bonds between ligands and the hinge region of
the binding site are almost universally present [7]. Adding
this kind of additional information to the docking has
been shown to improve enrichment, though this may
come at the expense of a reduction in ability to identify
novel chemotypes [5].
Although we have not compared our method directly with
these constrained docking methods, we would anticipate
that the enrichments seen would be quite similar (if not
Bar chart illustrating filtering rates for actives vs. decoys with PKC Figure 10
Bar chart illustrating filtering rates for actives vs. decoys with PKC. The percentages of actives (true positives) and 
decoys (false positives) that remain in the docked database after each of the pharmacophore filters. The absolute number in 
each group of compounds is marked at the top of the bars.
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better with constrained docking because the conforma-
tional search done by the docking program is biased in
favor of solutions that fit the constraints). However, the
great advantage of the pharmacophore filtering method is
that it allows the modeler to change his or her mind about
which features are most important for a productive bind-
ing interaction without having to go back and redo the
docking runs. A typical pharmacophore filtering run on a
file of 100,000 docked poses takes only a few minutes,
whereas the docking runs themselves can take days or
weeks. It is therefore possible to quickly test multiple fil-
tering combinations and variations, and to develop
refined hit sets focusing on different regions of the bind-
ing site.
It is also possible to adjust the stringency of the filters to
tune the number of compounds that are output from the
pharmacophore filtering, to be sent on to the next step in
the screening. If the hit set is to be assayed experimentally,
the number of compounds can be scaled according to the
resources available and the throughput level of the assay.
If more detailed calculations are to be done, such as MM/
PBSA scoring or other free energy estimations of binding
affinity, the size of the hit set can be adjusted according to
the available computational resources and time.
A final advantage of our pharmacophore filtering method
is the ability to easily go back and look for compounds
occupying specific sub-pockets in the binding site, as for
example with CDK2 and residue Lys 89 on the top edge of
the binding site. It is also possible to explore novel bind-
ing modes, to look for compounds that interact with the
target receptor in ways that are not seen with existing
known ligands.
The three test cases presented here are of course not suffi-
cient to provide an estimate of the statistical significance
of the improvement in performance of this method over
traditional docking + scoring methods, and in fact for two
of the targets (neuraminidase and CDK2) the improve-
ment seen with the pharmacophore filtering method ver-
sus Glide docking with compounds ranked by Gscore is
Enrichment plot for PKC Figure 11
Enrichment plot for PKC. Comparison of the percentage of known actives retrieved vs. the percentage of the test database 
screened for the pharmacophore filtering method and traditional docking + scoring methods.
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very slight. However, there is no way to know a priori
whether or not a given docking + scoring method will per-
form well for a given target. Many published studies com-
paring docking programs to one another have shown
widely varying results for different targets [5,48,49]. In
this study, although Glide performs very well with neu-
raminidase and CDK-2, GOLD is more successful with the
third target, the PKC C1 domain.
We also believe that human oversight and intervention in
any computational modeling work is essential. In virtual
screening, time spent thinking carefully about the receptor
binding site and interactions made by ligands binding in
it would pay off in a greater understanding of the struc-
tural characteristics of the system – knowledge that could
be useful for subsequent refinement into leads of the hits
out of the screening database. Our rapid and resource-
wise undemanding method facilitates this thoughtful
approach to one of the challenges in drug design.
Conclusion
In summary, combining docking with pharmacophore
searches as a post-processing filter allows the advantages
of both methods to be fully exploited. The docking pro-
gram is used to fit the ligands into the binding site in as
wide a variety as possible of reasonable ways. Put another
way, we are using it as a conformation generator for con-
formations that fit into the active site. Compared to a tra-
ditional pharmacophore search, where conformations for
each molecule in the database are pre-generated to be dis-
persed over all low-energy conformational space, the
docking program allows us to focus on a set of conforma-
tions for each molecule that all fit into the binding site.
Additionally, the docking program performs the align-
ment of all the conformations to one another, which is
much simpler than dealing with the combinatorial explo-
sion of ways in which the active compounds can be
aligned and the number of features to include. Post-
processing the docking results with pharmacophore filter-
ing allows us to bypass to a large extent the difficulty with
scoring functions, which is that while they are generally
good at producing reasonable docked poses of a molecule
in a binding site, they are not necessarily good at discrim-
inating between good binders and poor binders, probably
due to the non-linear nature of ligand-receptor recogni-
tion. The pharmacophore filtering method greatly
increases the likelihood that the best and/or most correct
pose is selected from the set of docked poses, regardless of
the numerical value of its docking score. This method has
been used successfully in several virtual screening projects
in our laboratory, one for inhibitors of Met tyrosine
kinase [50], and others which will be reported separately.
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